ArticleThe Journal of antimicrobial chemotherapy2025
Performance of disc diffusion and gradient strip test on different Mueller-Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1.The Journal of antimicrobial chemotherapy · 2026Article
- Beyond Mueller-Hinton agar: comparative evaluation of agar media for antibiotic susceptibility testing and implications for resource-limited laboratory settings.Microbiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCefiderocol antimicrobial susceptibility testing requires standardized iron levels to produce consistent results. Here we assessed the analytical performances of two commercialized broth microdilution (BMD) methods (Bruker's UMIC and Liofilchem's ComASP), of disc diffusion (DD) and the gradient strip method on a collection of clinical carbapenem-resistant-Pseudomonas aeruginosa (CRPA) isolates.
methodsA collection of 117 WGS-CRPA was used. Cefiderocol susceptibility was determined (i) by manual BMD (reference method) using iron-depleted Mueller-Hinton (ID-MH), (ii) with the UMIC and ComASP BMD panels, (iii) by DD and (iv) using the gradient strip test, these latter two on bioMérieux MH-agar, Liofilchem MH-agar, and in-house-produced iron-depleted (ID)-MH agar plates.
resultsCefiderocol MIC50 and MIC90 were 1 and 4 mg/L, respectively. Eighteen isolates (15.4%) were classified as resistant (MIC > 2 mg/L) according to the standard EUCAST-based BMD. Overall, the ComASP panel showed the highest essential agreement (EA) with the standard BMD (82.1%), with a bias of -8.5%, and categorical agreement (CA) of 94%. The UMIC panel exhibited an EA of 74.4%, with a bias of 47%, and CA of 78.6%, exhibiting a tendency to overestimate the MICs. The EAs of the gradient strip test on bioMérieux-MH, Liofilchem-MH and ID-MH agar plates were 40.2%, 45.3% and 63.2%, respectively. Considering only categorizable results, the CAs of DD were 92.7%, 94.4% and 93.9%, respectively.
conclusionsThe commercial ComASP panel may be used for cefiderocol testing of P. aeruginosa clinical isolates in diagnostic laboratories, ideally in combination with another method, such as the EUCAST-based DD. However, the standard manual BMD should still be performed to confirm the result when MICs are close to the breakpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.